ERBB2 and breast carcinoma: In these cases, it could be interesting to evaluate the ability of our profile to predict the efficacy of adjuvant chemotherapy in breast cancer and the response of non-operable NSCLC by using activated HER2 lung cancer cell lines as the reference to avoid tissue-origin bias.